Investment Thesis Report: Clinical Research

As processes within clinical trials continue to progress, technology will become more central in creating efficiencies. Covid-19 has forced many elements of the clinical trial process to shift, becoming more technology dependent. This shift has changed the way regulators, providers, and patients operate within the clinical trial process. With value-based care becoming more central, efforts to find new therapies are increasing each year, which further increases the pressure on the clinical trial system. With these tailwinds moving the industry forward at a rapid pace, FCA is interested in making more investments in tech enabled start-ups solving inefficiencies in the clinical trial process.

Here is a brief excerpt from this report: “While clinical research is on the rise globally, barriers continue to persist that inhibit researchers from completing trials. Interestingly, only half of the drugs rejected in the FDA approval process are due to lack of efficacy. In many cases, failures to submit forms and meet FDA timelines cause trials to derail. In later stages, trial delays can be attributed to management inexperience, unexpected costs, and poor communication with FDA reviewers”.

Click here to view the PDF of the full report

Thanks to our summer intern, William Reed, for his work in preparing this investment thesis report.

A special thanks to William Blair for allowing FCA to incorporate some of their company specific research.